Skip to main content
SpringerLink
Log in

Pembrolizumab (Keytruda®)-assoziierte Hypotonia bulbi

Pembrolizumab (Keytruda®) associated ocular hypotony

  • Kasuistiken
  • Published:
Die Ophthalmologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Roberts K, Culleton V, Lwin Z, O’Byrne K, Hughes BG (2017) Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol 13(4):277–288. https://doi.org/10.1111/ajco.12698

    Article  PubMed  Google Scholar 

  2. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA (2018) Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina 38(6):1063–1078. https://doi.org/10.1097/iae.0000000000002181

    Article  CAS  PubMed  Google Scholar 

  3. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_de.pdf. Zugegriffen: 15. Dez. 2022

  4. Mihailovic N, Dyballa J, Herz S, Fluck M, Alnawaiseh M, Merté RL, Eter N (2020) Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma. Ophthalmologe 117(5):467–471. https://doi.org/10.1007/s00347-019-00963-z

    Article  PubMed  Google Scholar 

  5. Wang Q, Thau A, Levin AV, Lee D (2019) Surv ocular hypotony: a comprehensive review. Surv Ophthalmol 64(5):619–638. https://doi.org/10.1016/j.survophthal.2019.04.006

    Article  PubMed  Google Scholar 

  6. Golash V, Almeida G (2020) Pembrolizumab-related bilateral ocular hypotony, uveitis, cataracts, exudative retinal, and choroidal detachments: an unusual success story. J Immunother 43(9):283–285. https://doi.org/10.1097/cji.0000000000000328

    Article  CAS  PubMed  Google Scholar 

  7. Lee J, Shin JY, Lee JS, Lee SC, Hong MH, Lee CS (2020) Recurrent sympathetic ophthalmia with annular choroidal detachment after pembrolizumab treatment: a case report. Ocul Immunol Inflamm 28(6):864–867. https://doi.org/10.1080/09273948.2019.1604975

    Article  CAS  PubMed  Google Scholar 

  8. de Vries EW, Schauwvlieghe A‑S, Haanen JB, de Hoog J (2022) Bilateral serous retinal detachment and uveitis associated with pembrolizumab treatment in metastatic melanoma. Retin Cases Brief Rep 16(4):430–434. https://doi.org/10.1097/icb.0000000000000999

    Article  PubMed  Google Scholar 

  9. Nguyen M, Islam MR, Lim SW, Sahu A, Tamjid B (2019) Pembrolizumab induced ocular hypotony with near complete vision loss, interstitial pulmonary fibrosis and arthritis. Front Oncol 9:944. https://doi.org/10.3389/fonc.2019.00944

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gupta P, Gupta A, Gupta V, Singh R (2009) Successful outcome of pars plana vitreous surgery in chronic hypotony due to uveitis. Retina 29(5):638–643. https://doi.org/10.1097/iae.0b013e31819a5fd8

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Augenheilkunde, Universitätsklinikum Münster, Domagkstr. 15, 48149, Münster, Deutschland

    S. Dierse, S. Al-Naweiseh, E. Esser, V. Englmaier, N. Eter & C. R. Clemens

Authors
  1. S. Dierse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Al-Naweiseh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Esser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Englmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Eter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. R. Clemens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Dierse.

Ethics declarations

Interessenkonflikt

N. Eter macht folgende Angaben: grants or contracts from any entity: Novartis, Bayer to department; consulting fees: Novartis, Bayer, Roche, Apellis, Allergan, Alcon; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Novartis, Bayer, Roche, Apellis, Allergan; support for attending meetings and/or travel: Roche. S. Dierse, S. Al-Naweiseh, E. Esser, V. Englmaier und C.R. Clemens geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patient/-innen zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern/Vertreterinnen eine schriftliche Einwilligung vor.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dierse, S., Al-Naweiseh, S., Esser, E. et al. Pembrolizumab (Keytruda®)-assoziierte Hypotonia bulbi. Ophthalmologie 120, 1042–1044 (2023). https://doi.org/10.1007/s00347-023-01808-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-023-01808-6

Search

Navigation